Click HERE to register.

Overview

The Miami Leukemia Symposium is proud to present an exciting group of world-renowned clinicians and researchers to discuss the modern management of patients with acute and chronic leukemias and the role of stem cell transplantation for these patients. This venue will provide clinicians with a forum to discuss a wide range of topics including, the genetic/epigenetic landscape of myeloid neoplasms, the clinical management of acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia, as well as the indications for transplantation in each of these diseases.

Learning Objectives

The intended result of this activity is increased knowledge, competence, performance and skill, and enhanced patient care. At the conclusion of this activity participants will be able to:

• Assess progress made in diagnosis and management of myeloid neoplasms in last four decades
• Focus on reviewing molecular diagnostic approaches (NGS, MRD)
• Use new treatment approaches in the clinic
• When to send a patient for transplant assessment
• Which transplant modalities are considered optimal
• Appraise and evaluate the  current literature regarding the diagnosis and management of BPDCN
• Illustrate the diagnostic criteria which separates BPDCN from related and pathologically similar diseases
• Explain the underlying pathogenesis of BPDCN
• Integrate new molecular insights underpinning BPDCN with targeted management strategies
• Review the literature outlining the development of TKIs in CML
• Analyze and debate the available approved agents and when to sequence them in treating patients
• Debate the current challenges in CML and appraise ongoing solutions
• Review the recently approved new agents since 2017 in AML (there are at least 8)
• Debate the optimal timing and approved use of these agents in frontline, and relapsed AML, and in younger vs. older adults
• Understand the mechanism of action of these new agents